AbbVie Q2 EPS down 32.5% to $0.52, revenue up 6.6% to $15.423 bln.

• AbbVie reports Q2 diluted EPS of $0.52, a 32.5% decrease • Adjusted diluted EPS of $2.97, a 12.1% increase • Net revenues of $15.423 billion, a 6.6% increase • Immunology portfolio net revenues up 9.5% to $7.631 billion • Neuroscience portfolio net revenues up 24.2% to $2.683 billion • Acquired IPR&D and milestones expense unfavorably impacted EPS by $0.42 per share.

AbbVie Inc. (NYSE: ABBV) announced its second-quarter 2025 financial results, highlighting a mixed performance across its diverse portfolio. The company reported diluted earnings per share (EPS) of $0.52 on a GAAP basis, a significant decrease of 32.5% compared to the same period last year. However, the adjusted diluted EPS stood at $2.97, marking a 12.1% increase year-over-year.

Total net revenues for the second quarter reached $15.423 billion, representing a 6.6% increase on a reported basis and a 6.5% increase on an operational basis. The immunology portfolio, a key driver of growth, saw its net revenues rise by 9.5% to $7.631 billion. Meanwhile, the neuroscience portfolio posted a robust increase of 24.2% to $2.683 billion.

However, the company faced an unfavorable impact of $0.42 per share related to acquired intellectual property research and development (IPR&D) and milestones expense, which negatively affected the EPS. This expense accounted for 5.3% of net revenues.

The company also provided an updated outlook for 2025, raising its adjusted diluted EPS guidance range from $11.67 - $11.87 to $11.88 - $12.08. This revision includes the unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2025.

AbbVie's strong pipeline progress and strategic investments were highlighted by several recent events, including the FDA approval of Rinvoq for giant cell arteritis and positive topline results from a Phase 3 study evaluating Rinvoq in adult and adolescent patients with severe alopecia areata. Additionally, the company announced plans to acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery.

References:
[1] https://www.marketscreener.com/news/abbvie-reports-second-quarter-2025-financial-results-ce7c5fdddb8df121